PubMed · 2000 · 121 citations · 19 references
MedicineHematologyOncologyChemotherapyHematologic OncologyTransplant ImmunologyChemotherapy In Hematologic MalignanciesDonor-recipient CompatibilityEngraftment MonitoringHematologic Malignancy TherapyHistocompatibilityHla MatchingAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TransplantationAcute Myeloid Leukemia TreatmentHla Donor-recipient MatchingHla Matching In TransplantationSibling Donor MatchingTransplantation For Hematologic Malignancies
Allogeneic bone marrow transplantation is an effective postremission strategy for patients with acute myelogenous leukemia (AML) in first complete remission (CR). The value of administering consolidation chemotherapy before human leukocyte antigen (HLA)-identical sibling transplantation is not established. Outcomes of patients with AML in first CR receiving no consolidation therapy, standard-dose cytarabine consolidation therapy, and high-dose cytarabine consolidation therapy before HLA-identical sibling transplantation were compared. Five-year treatment-related mortality rates were 30% (95% confidence interval [CI], 18% to 42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 28%) in those receiving standard-dose cytarabine consolidation, and 24% (95% CI, 17% to 31%) in those receiving high-dose cytarabine (P = NS). Five-year cumulative incidences of relapse were 19% (10% to 30%), 21% (16% to 27%), and 17% (11% to 24%), respectively (P = NS). Five-year probabilities of leukemia-free survival were 50% (36% to 63%), 56% (49% to 63%), and 59% (50% to 66%), respectively (P = NS). Five-year probabilities of overall survival were 60% (46% to 71%), 56% (49% to 63%), and 60% (51% to 67%), respectively (P = NS). The data indicate that postremission consolidation with cytarabine before allogeneic transplantation for AML in first CR is not associated with improved outcome compared to proceeding directly to transplantation after successful induction. (Blood. 2000;96:1254-1258)
19
Statistical Models Based on Counting Processes
Xavier Bry, Per Kragh Andersen, Ørnulf Borgan et al. · Population · 1997 · 2.9K citations
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Robert J. Mayer, Roger B. Davis, Charles A. Schiffer et al. · New England Journal of Medicine · 1994 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +13
Peter A. Cassileth, David P. Harrington, Frederick R. Appelbaum et al. · New England Journal of Medicine · 1998 · 609 citations · Full text
Medicine, Oncology, Chemotherapy +13
Jean‐Luc Harousseau, Jean‐Yves Cahn, B. Pignon et al. · PubMed · 1997 · 317 citations
Medicine, Hematology, Oncology +17